Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Lifecore Biomedical (NASDAQ: LFCR) announced a significant leadership change with the appointment of Ryan Lake as the new Chief Financial Officer, effective September 3, 2024. Lake, an experienced CDMO industry financial executive, succeeds John Morberg, who is stepping down to pursue other opportunities. Lake brings valuable experience from his previous role as CFO of Societal CDMO, where he led the company's transition into a dedicated CDMO and played a key role in its strategic growth and eventual acquisition by CoreRx.
CEO Paul Josephs expressed confidence in Lake's ability to drive Lifecore's growth strategy, citing his expertise in investor relations, financial strategy, and experience in navigating complex transactions within the CDMO space. Lake's appointment is seen as a strategic move to enhance Lifecore's position in the CDMO market and drive long-term value for stakeholders.
Lifecore Biomedical (NASDAQ: LFCR) reported its fiscal year 2024 results, showing strong revenue growth of 24.2% to $128.3 million. The company's CDMO business grew 27%, while its HA raw material manufacturing increased 18%. Gross profit rose 49.5% to $41.9 million, with margin expanding to 32.6%.
Key highlights include:
- Net income from continuing operations of $9.3 million, compared to a loss of $64.2 million in FY2023
- Adjusted EBITDA increased 82.2% to $20.2 million
- New 5-head isolator filler expected to be GMP-ready in September 2024
For fiscal 2025, Lifecore projects revenue between $126.5-$130 million and Adjusted EBITDA of $19-$21 million.
Lifecore Biomedical has announced a new cooperation agreement with 22NW, which will result in the addition of four new members to its Board of Directors. The new board members include Humberto Antunes, Jason Aryeh, Paul Johnson, and Matthew Korenberg. This change is effective immediately following the 2023 Annual Meeting of Stockholders. The agreement allows Lifecore to avoid a proxy fight and focuses on strengthening its business strategy. 22NW will withdraw its nomination notice and demand for a special meeting. The board will recommend declassifying itself for one-year terms starting in 2025. Large stockholders Legion Partners and Wynnefield Capital have also entered into support agreements. The full agreement will be filed with the SEC.
Lifecore Biomedical announced the granting of restricted stock unit (RSU) and performance stock unit (PSU) awards to Paul Josephs, their new President and CEO. The RSU comprises 525,000 shares and the PSU up to 1,500,000 shares. Approved by Lifecore's compensation committee, these inducement awards were granted under Nasdaq Listing Rule 5635(c)(4) and Lifecore's Equity Inducement Plan. The RSU will vest in tranches over five years, while the PSU's vesting depends on meeting share price performance targets within a five-year period. This move aims to align Josephs’ incentives with company performance and shareholder value.
Lifecore Biomedical (NASDAQ: LFCR) has announced several initiatives to improve liquidity, resulting in an additional $8 million of non-dilutive liquidity. This brings the total non-dilutive incremental liquidity to $18.5 million for fiscal year 2024. Key measures include amendments with lenders and the winding down of subsidiary Curation Foods.
On May 2, 2024, Lifecore secured a $5.5 million prepayment from a term lender. Additionally, a 'first-in, last-out' tranche amendment with an ABL lender added $2.5 million in revolving loan capacity, though it will increase annual interest expenses by $44,000.
The company also finalized an assignment for the benefit of creditors for Curation Foods. As of April 21, 2024, Lifecore reported total debt and cash of $178.9 million and $3.0 million, respectively, which would be $178.9 million and $11.0 million on a pro forma basis.
Moreover, amendments to the 2024 Annual Incentive Plan will see executives compensated in fully vested shares rather than cash.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.